Abstract

Aims

Psoriasis is a common chronic inflammatory T-helper cell-1/17 mediated skin disease. Recent studies suggest that psoriasis, particularly if severe, may be an independent risk factor for atherosclerosis, myocardial infarction (MI), and stroke. We conducted a cohort study using the General Practice Research Database to determine if severe psoriasis patients have an increased risk of cardiovascular (CV) mortality.

Methods and results

Severe psoriasis was defined as patients who received a psoriasis diagnosis and systemic therapy consistent with severe psoriasis (n = 3603). Up to four unexposed patients without psoriasis were selected from the same practices and start dates for each psoriasis patient (n = 14 330). For every death, the cause was determined by review of the electronic medical record. Severe psoriasis was an independent risk factor for CV mortality (HR 1.57; 95% CI 1.26, 1.96) when adjusting for age, sex, smoking, diabetes, hypertension, and hyperlipidaemia. Overall, severe psoriasis patients experienced one extra CV death per 283 patients per year, even when adjusting for major CV risk factors. The relative risk of CV mortality was modified by age. For example, the RR of CV death for a 40-year-old and 60-year-old with severe psoriasis was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively. The findings were robust to multiple sensitivity analyses.

Conclusion

Patients with severe psoriasis have an increased risk of CV mortality that is independent of traditional CV risk factors. Additional studies are needed to determine the mechanism of this association and the impact that control of psoriasis has on CV risk.

See page 902 for the editorial comment on this article (doi:10.1093/eurheartj/ehq042)

Introduction

Psoriasis is a common, chronic inflammatory disease of the skin and joints that affects ∼2–4% of the general adult population.1,2 Psoriasis is associated with impairments in health-related quality of life, even in mild cases, and is associated with excess all-cause mortality in patients with severe disease.3,4 The cause of psoriasis remains unknown; however, its pathogenesis involves a complex interaction between genetics, the immune system, and environmental exposures.

Recent evidence suggests that chronic psoriasis may be associated with other conditions that are caused, in part, by chronic inflammation.5 For example, helper T-cells type 1 (Th-1) chronic inflammation characteristic of psoriasis is also central to the pathophysiology of other conditions such as insulin resistance, atherosclerosis, and plaque rupture leading to thrombotic events.6,7 Patients with psoriasis have increased prevalence of traditional cardiovascular (CV) risk factors such as diabetes,8 hypertension,9 metabolic dyslipidaemia,10 tobacco use,11 and obesity. Furthermore, even after adjusting for these risk factors, recent epidemiological studies support an independent association between psoriasis and myocardial infarction (MI), coronary artery disease, stroke, diabetes, endothelial cell dysfunction, and atherosclerosis.12–15

Despite evidence of increased all-cause mortality4 in patients with severe psoriasis and accumulating evidence of increased prevalence of CV risk factors, there is a paucity of data examining whether psoriasis is associated with increased mortality due to CV disease (CVD) after adjusting for CV risk factors. The purpose of the present study was to determine if patients with severe psoriasis have an increased risk of CV mortality.

Methods

Study population and data source

The study was conducted and is reported based on recommendations of the STROBE statement.16 The study population was derived from the General Practice Research Database (GPRD), a medical records database in the UK that was established for epidemiological research in 1987.17 The GPRD is representative of the UK population in terms of age and sex, as well as geographic distribution. Approximately 5% of the UK is represented in this database, and it contains over 9 million patient records with 40 million person-years of follow-up. Over 99% of patients through the National Health Service are registered through their general practitioner (GP) and the database captures both diagnoses and medications. The GPRD has been shown to capture information on diagnoses and treatments from specialists through the GP's electronic medical record.18 General practitioners received specific training and incurred penalties in order to ensure high quality data. The data are also audited for completeness and a practice receives an up-to-standard (UTS) designation when at least 95% of relevant prescriptions and diagnoses are captured electronically. This database has also been studied in numerous validation studies, including those of psoriasis and CVD, to demonstrate that it captures these outcomes accurately.1,12

Time period and age eligibility

Data were obtained between 1987 and 2002 for patients who were 18 or older at the date their person-time began.

Definition of exposure

We defined severe psoriasis patients as those with a diagnostic code of psoriasis, and history of systemic therapy consistent with severe psoriasis. Systemic therapy included phototherapy, psoralen plus ultraviolet A radiation, methotrexate, azathioprine, cyclosporine, oral retinoids (etretinate, acitretin), hydroxyurea, and mycophenolate mofetil. Of note, during the time period that this study was conducted, biologic therapies were not approved for use for psoriasis in the UK. The unexposed population (controls) was composed of patients with no history of a psoriasis diagnostic code.

Sampling of exposed and unexposed cohorts

All patients with severe psoriasis (as defined above) who were age 18 or older at their index date and had at least 1 day of observation time were included. For patients with severe psoriasis, their index date was the first date on or after the first diagnosis of psoriasis in which the patient received a code for treatment consistent with severe disease. For patients without psoriasis, their index date was the date of a medical record entry which was within 60 days of the psoriasis index date. Up to four unexposed subjects who were age 18 or older at their index date were randomly selected for each psoriasis patient, matched on practice, date of registration in the practice, and psoriasis index date (corresponding to a medical record date of the unexposed patient). The matching on dates occurred as follows: registration: ±90 days (if registration date ≥1980, otherwise ±5 years), index date: ±60 days. The purpose of matching on practice, registration, and index dates was to ensure that patients with and without psoriasis were evaluated by similar physicians during the same time period to account for potential variations in medical practice and to allow for similar degrees of opportunity for GPs to identify medical conditions in psoriasis and non-psoriasis patients.

Person-time calculation

For severe psoriasis patients, follow-up started at the latest of the date of when the patient could first be defined as having severe psoriasis (e.g. received a treatment code consistent with severe disease), was registered with the practice, or the practice was deemed UTS. For unexposed subjects, follow-up started at the latest date of when the patient was registered in the practice, the index date (matched to the psoriasis index date), and the practice was deemed UTS. For all groups, follow-up ended at the date of death, transfer out of the practice, or end of UTS.

Outcome of interest

The outcome of interest was CV death defined as diagnoses consistent with MI, stroke, peripheral vascular disease, arrhythmia, or left ventricular thrombus entered on or very close to the entry of death. For every death, the cause was determined by review of medical codes on or very near date of death by two physician reviewers blinded to exposure status (R.S.A. and A.L.N.). If there were discrepancies, a third blinded physician reviewer was utilized (J.M.G.). Agreement on cause of death was 96%.

Co-variables of interest

We identified traditional CV risk factors including age, sex, hypertension, diabetes, hyperlipidaemia, and smoking (current, former, never) by the presence of diagnostic codes. Body mass index was directly calculated from available data in the medical record.

Analysis

The sample size was determined by including the maximum eligible number of patients with severe psoriasis based on age criteria. We randomly selected up to four unexposed subjects per patient with psoriasis as additional matching yields minimal increases in statistical power. Data were summarized descriptively. Dichotomous variables were tested with Fisher's exact test. Continuous variables were tested with a t-test if they were normally distributed, or with the Wilcoxon test if the data were not normally distributed. We fit age- and sex-adjusted Cox models to determine the overall hazard ratio of CV death in psoriasis patients.19 When univariate Cox models indicated an association of psoriasis with CV death, we fit additional models with covariates included (described above) as well as models with age and sex interaction terms, to determine if the relative risk of CV death in psoriasis patients was different based on sex or age characteristics. The primary model includes major CV risk factors. Body mass index was recorded in about 69% of patients. Each dichotomous variable in the model was checked for proportionality while adjusting for the other covariates in the model by examining diagnostic log–log plots. We used the Greenland method of external adjustment to determine the degree to which our findings could be explained by an unknown or unmeasured confounder.20 Multiple sensitivity analyses were performed to test the underlying assumptions of our primary analysis. All analyses were performed using STATA 10.0, and a P-value of <0.05 was threshold for statistical significance, and P < 0.10 for interaction analysis.

Protection of human subjects

This study was approved by the University of Pennsylvania Institutional Review Board and by the Independent Scientific Advisory Committee of the Medicines and Healthcare Products Regulatory Agency of the United Kingdom Department of Health. The study was conducted in accordance with the Declaration of Helsinki.

Results

In this study, we identified 3603 patients with severe psoriasis, and 14 330 matched unexposed patients (Table 1). Patients with severe psoriasis patients were slightly older and more likely to be male and have established CV risk factors than patients without psoriasis including hypertension, hyperlipidaemia, tobacco use, Type 2 diabetes (P < 0.05 for all). Furthermore, the majority of patients with severe psoriasis were treated with methotrexate (Table 2).

Table 1

Characteristics of study group

Characteristics Unexposed (n = 14 330) Psoriasis (n = 3603) 
Sex (male) 5783 (40.4%) 1750 (48.6%), P < 0.001 

 
Age (year)#  P < 0.001 
 Mean ± SD 49.7 ± 19.3 52.2 ± 16.7 
 Median (IQR) 48 (33–65) 52 (39–66) 
Diabetes mellitus 737 (5.1%) 270 (7.5%), P < 0.001 
History of MI 375 (2.6%) 116 (3.2%), P = 0.052 
History of stroke 268 (1.9%) 89 (2.5%), P = 0.023 
History of TIA 243 (1.7%) 68 (1.9%), P = 0.432 
Hyperlipidaemia 842 (5.9%) 250 (6.9%), P = 0.019 
Hypertension 3049 (21.3%) 858 (23.8%), P = 0.001 

 
Smoking 
 Never 10 465 (73.0%) 2488 (69.1%) 
 Current 755 (5.3%) 241 (6.7%) 
 Former 3110 (21.7%) 874 (24.3%), P < 0.001 

 
BMIa 
 <25 5057 (51.2%) 1025 (42.1%) 
 ≥25 and <30 3291 (33.3%) 860 (35.4%) 
 ≥30 1522 (15.4%) 548 (22.5%), P < 0.001 

 
Reason for end of study 
 Death 790 (5.5%) 297 (8.2%) 
 End of UTS 11247 (78.5%) 2860 (79.4%) 
 Transfer out 2293 (16.0%) 446 (12.4%), P < 0.001 
Characteristics Unexposed (n = 14 330) Psoriasis (n = 3603) 
Sex (male) 5783 (40.4%) 1750 (48.6%), P < 0.001 

 
Age (year)#  P < 0.001 
 Mean ± SD 49.7 ± 19.3 52.2 ± 16.7 
 Median (IQR) 48 (33–65) 52 (39–66) 
Diabetes mellitus 737 (5.1%) 270 (7.5%), P < 0.001 
History of MI 375 (2.6%) 116 (3.2%), P = 0.052 
History of stroke 268 (1.9%) 89 (2.5%), P = 0.023 
History of TIA 243 (1.7%) 68 (1.9%), P = 0.432 
Hyperlipidaemia 842 (5.9%) 250 (6.9%), P = 0.019 
Hypertension 3049 (21.3%) 858 (23.8%), P = 0.001 

 
Smoking 
 Never 10 465 (73.0%) 2488 (69.1%) 
 Current 755 (5.3%) 241 (6.7%) 
 Former 3110 (21.7%) 874 (24.3%), P < 0.001 

 
BMIa 
 <25 5057 (51.2%) 1025 (42.1%) 
 ≥25 and <30 3291 (33.3%) 860 (35.4%) 
 ≥30 1522 (15.4%) 548 (22.5%), P < 0.001 

 
Reason for end of study 
 Death 790 (5.5%) 297 (8.2%) 
 End of UTS 11247 (78.5%) 2860 (79.4%) 
 Transfer out 2293 (16.0%) 446 (12.4%), P < 0.001 

Unless notes otherwise, P-values are derived using Fisher exact test. MI, myocardial infarction, TIA, transient ischaemic attack, BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); SD, standard deviation; IQR, interquartile range.

aData for BMI were available for 69% of the patients.

#Wilcoxon test.

Table 2

Systemic therapies received by patients with severe psoriasis (n=3603)

Systemic therapy Number of patients with severe psoriasis (%) 
Methotrexate 2114 (58.7%) 
Psoralen or phototherapy 607 (16.9%) 
Azathioprine 582 (16.2%) 
Cyclosporine 390 (10.8%) 
Etretinate or acetretin 333 (9.2%) 
Hydroxyurea 208 (5.8%) 
Mycophenolate mofetil 9 (0.3%) 
Systemic therapy Number of patients with severe psoriasis (%) 
Methotrexate 2114 (58.7%) 
Psoralen or phototherapy 607 (16.9%) 
Azathioprine 582 (16.2%) 
Cyclosporine 390 (10.8%) 
Etretinate or acetretin 333 (9.2%) 
Hydroxyurea 208 (5.8%) 
Mycophenolate mofetil 9 (0.3%) 

Percentages do not add up to 100 because patients could have received more than one systemic therapy.

The incidence of mortality due to CVD in unexposed subjects and psoriasis subjects is shown in Table 3. The frequency of deaths due to CVD was higher in patients with severe psoriasis. The unadjusted overall risk of mortality due to CVD per 1000 person-years was significantly increased (P = 0.002) in patients with severe psoriasis patients (8.75, 95% CI 7.18–10.56) compared with unexposed patients (6.19, 95% CI 5.51–6.93). After adjusting for traditional CV risk factors (age, sex, hyperlipidaemia, hypertension, smoking, diabetes), severe psoriasis was an independent risk factor for death due to CVD (HR 1.57; 95% CI 1.26, 1.96) (Table 4). On the basis of these analyses, we estimate that each year there is approximately one excess death from CVD per 283 severe psoriasis patients. There was no statistical interaction (also known as effect modification) between psoriasis and sex (P = 0.99); however, there was an interaction between psoriasis and age (P = 0.07). For example, the adjusted relative risk of CV mortality in a severe psoriasis patient who is 40 years old and 60 years old was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively. The adjusted excess risk of CV mortality in a 40- and 60-year-old psoriasis patient was 6.05 deaths/10 000 person-years and 41.30 deaths/10 000 person-years, respectively.

Table 3

Incidence of cardiovascular disease mortality in patients with psoriasis compared with patients without psoriasis (unexposed population)

Variable Unexposed (n = 14 330) Psoriasis (n = 3603) 
Follow-up time (year) 
 Mean ± SD 3.4 ± 2.8 3.4 ± 2.7 
 Median (IQR) 2.6 (1.2–5.0) 2.7 (1.2–5.1) 

 
Number of person-years 48 661.8 12 346.3 
Number of CVD mortality cases (%) 301 (2.1%)* 108 (3.0%)* 
Incidence per 1000 person-years (95% CI) 6.19 (5.51, 6.92) 8.75 (7.18, 10.56) 
Variable Unexposed (n = 14 330) Psoriasis (n = 3603) 
Follow-up time (year) 
 Mean ± SD 3.4 ± 2.8 3.4 ± 2.7 
 Median (IQR) 2.6 (1.2–5.0) 2.7 (1.2–5.1) 

 
Number of person-years 48 661.8 12 346.3 
Number of CVD mortality cases (%) 301 (2.1%)* 108 (3.0%)* 
Incidence per 1000 person-years (95% CI) 6.19 (5.51, 6.92) 8.75 (7.18, 10.56) 

CI, confidence interval; SD, standard deviation; IQR, interquartile range.

*P = 0.002

Table 4

Unadjusted and adjusted Cox proportional hazard regression models of the risk of cardiovascular disease mortality in severe psoriasis compared with unexposed patients

Covariate Model hazard ratio (95% CI) 
 Severe psoriasis 
Unadjusted analysis 
 Psoriasis 1.42 (1.14, 1.76) 

 
Adjusted for age and sex 
 Psoriasis 1.57 (1.26, 1.96) 
 Age per year 1.10 (1.09, 1.11) 
 Sex (male) 1.61 (1.32, 1.95) 

 
Primary model (adjusted for major cardiovascular risk factors)a 
 Psoriasis 1.57 (1.26, 1.96) 
 Age per year 1.10 (1.09, 1.11) 
 Sex (male) 1.54 (1.27, 1.88) 
 Hypertension 1.25 (1.01, 1.53) 
 Hyperlipidaemia 0.75 (0.42, 1.34) 
 Hx of diabetes 2.25 (1.68, 3.02) 
 Smoking (current vs. never) 1.33 (0.95, 1.86) 
 Smoking (former vs. never) 1.31 (0.98, 1.74) 
Covariate Model hazard ratio (95% CI) 
 Severe psoriasis 
Unadjusted analysis 
 Psoriasis 1.42 (1.14, 1.76) 

 
Adjusted for age and sex 
 Psoriasis 1.57 (1.26, 1.96) 
 Age per year 1.10 (1.09, 1.11) 
 Sex (male) 1.61 (1.32, 1.95) 

 
Primary model (adjusted for major cardiovascular risk factors)a 
 Psoriasis 1.57 (1.26, 1.96) 
 Age per year 1.10 (1.09, 1.11) 
 Sex (male) 1.54 (1.27, 1.88) 
 Hypertension 1.25 (1.01, 1.53) 
 Hyperlipidaemia 0.75 (0.42, 1.34) 
 Hx of diabetes 2.25 (1.68, 3.02) 
 Smoking (current vs. never) 1.33 (0.95, 1.86) 
 Smoking (former vs. never) 1.31 (0.98, 1.74) 

Interaction term for sex was not statistically significant (P = 0.99), but was for age (P = 0.07). CI, confidence interval.

aHypertension, hyperlipidaemia, diabetes, and smoking status.

The results were robust to a variety of sensitivity analyses shown in Table 5. Body mass index was not included in the primary model as its inclusion did not alter the association between psoriasis and CV death and it was captured in only 69% of patients (Table 5). Finally, analysing our data using an external adjustment approach suggests that such an unknown or unmeasured confounder would have to be common in the general population (prevalence of 20%), and have a strong association with psoriasis (OR 2.67 or greater) and a very strong association (OR 6.5 or greater) with CV death in order to render our findings null.20

Table 5

Sensitivity analysis hazard ratio point estimates

Covariate n Psoriasis n Controls Model hazard ratio (95% CI) 
Primary analysis 3603 14 330 1.57 (1.26, 1.96) 
Inclusion of patients with at least 1 GP visit per year on average 3563 13 643 1.54 (1.23, 1.93) 
Primary model excluding patients with history of myocardial infarction, stroke, and/or TIA or atherosclerotic disease 3310 13 335 1.56 (1.20, 2.04) 
Primary model with exclusion of methotrexate 1489 14 330 2.04 (1.51, 2.74) 
Primary model with exclusion of oral retinoids or cyclosporine 2914 14 330 1.51 (1.18, 1.94) 
Primary model restricted to patients who received oral retinoids 333 14 663 1.59 (0.97, 2.60) 
Primary model with exclusion of psoriatic arthritis 2375 14 330 1.52 (1.19, 1.94) 
Primary model with BMI includeda 2433 9870 1.66 (1.19, 2.30) 
Primary model without BMI included in those who had BMI measureda 2433 9870 1.64 (1.18, 2.27) 
Inclusion of patients with at least 6 months of person time 3246 12 766 1.66 (1.30, 2.11) 
Primary model after matching cases to controls by age (±5 years) and sexb 3603 7205 1.59 (1.23, 2.04) 
Covariate n Psoriasis n Controls Model hazard ratio (95% CI) 
Primary analysis 3603 14 330 1.57 (1.26, 1.96) 
Inclusion of patients with at least 1 GP visit per year on average 3563 13 643 1.54 (1.23, 1.93) 
Primary model excluding patients with history of myocardial infarction, stroke, and/or TIA or atherosclerotic disease 3310 13 335 1.56 (1.20, 2.04) 
Primary model with exclusion of methotrexate 1489 14 330 2.04 (1.51, 2.74) 
Primary model with exclusion of oral retinoids or cyclosporine 2914 14 330 1.51 (1.18, 1.94) 
Primary model restricted to patients who received oral retinoids 333 14 663 1.59 (0.97, 2.60) 
Primary model with exclusion of psoriatic arthritis 2375 14 330 1.52 (1.19, 1.94) 
Primary model with BMI includeda 2433 9870 1.66 (1.19, 2.30) 
Primary model without BMI included in those who had BMI measureda 2433 9870 1.64 (1.18, 2.27) 
Inclusion of patients with at least 6 months of person time 3246 12 766 1.66 (1.30, 2.11) 
Primary model after matching cases to controls by age (±5 years) and sexb 3603 7205 1.59 (1.23, 2.04) 

CI, confidence interval; TIA, transient ischaemic attack; GP, general practitioner; BMI; body mass index.

aBMI is included in n = 12 303 or 69% of patients.

bTwo-to-one matching using original controls.

Discussion

The results of this study demonstrate that patients with severe psoriasis have a clinically significant 57% increased risk of CV death beyond the risk of death associated with traditional CV risk factors. On the basis of our data, a patient with severe psoriasis has an excess risk of CV death attributable to psoriasis of 1 in 283 patients per year. The risk of CV mortality in patients with severe psoriasis was not explained by major cardiac risk factors identified in routine medical practice, suggesting that severe psoriasis may be an independent risk factor for CV death. Moreover, the relative risk of CV death associated with severe psoriasis was highest in younger individuals suggesting a process of accelerated CVD in younger severe psoriasis patients. Therefore, it is of utmost importance that patients with severe psoriasis and their providers are aware of this increased risk and that these patients undergo appropriate risk assessment and implementation of prevention strategies.

The strengths of the current study include the utilization of a large population-based database that is well accepted for CV epidemiological studies and well-validated for psoriasis.1,9,17,18 In addition, the increased risk of CV death and point estimates were robust to a variety of sensitivity analyses (Table 5). We attempted to ensure that we were capturing patients who were seen regularly, minimizing the risk that information bias could explain the findings. In addition, even when patients with highest risk for CV death (i.e. those with history of MI, stroke or transient ischaemic attack, or atherosclerotic disease) were excluded, there was still a 56% increase in CV death associated with severe psoriasis. The results also persisted when examining the risk based on different treatments that theoretically could increase (e.g. cyclosporine, oral retinoids) or decrease (e.g. methotrexate) the risk of CVD.21,22 Thus, these findings suggest that the increased CV mortality is not due to treatment effect. The results also persisted when restricting the severe group to patients treated with therapy specific to severe psoriasis (e.g. oral retinoids), and when excluding patients with psoriatic arthritis suggesting that the findings are associated with severe skin psoriasis as opposed to misclassification with other diseases in which our systemic therapies may be indicated. Our data are consistent with recent studies that demonstrate that psoriasis is an independent risk factor for coronary artery disease,12–15 stroke,15,23 and MI.12,15 Our study builds upon previous findings that severe psoriasis patients have an increased relative risk CV mortality that is highest in younger individuals by evaluating outpatients, as opposed to hospitalized patients while also controlling for major CV risk factors.24

Psoriasis is a prototypical Th-1, 17 inflammatory disease, and Th-1 cellular secreted factors (e.g. intracellular adhesion molecule-1, TNF-α) are indeed involved in the pathogenesis of atherosclerosis and MI.25 Furthermore, given the accumulating evidence of inflammation playing a key role in development, progression, and complications of atherosclerosis,26 our findings have biological plausibility. Another Th-1 disease, rheumatoid arthritis, has also been shown to be associated with increased risk of MI27 and multi-vessel coronary disease.28 Recent studies have shown coronary microvascular dysfunction in patients who have chronic inflammation such as in rheumatoid arthritis or systemic lupus erythematosus.29 Patients with psoriasis have elevated high-sensitivity C-reactive protein30 which has been independently associated as a marker for increased risk of CV events.31,32 Finally, a recent study showed increased CVD defined as coronary artery disease, peripheral arterial disease, and stroke in patients with psoriasis,15 however this was not population-based and did not evaluate for CV mortality.

In addition to the inflammatory burden driving CAD risk in these disease states, there may be shared genetic risk which contributes as well. Genetics have been shown to play a key role in susceptibility to psoriasis33 and metabolic disorders, such as diabetes34 and dyslipidaemia,35 as well as coronary artery disease.36 Interestingly, replicated genetic loci identified in psoriasis such as CDKALI have been shown to be associated with Type 2 diabetes.37 Diabetes has long been known to be a potent risk factor for MI,38 and a shared genetic component between diabetes and psoriasis may contribute to our findings. Recent studies have found that psoriasis is an independent risk factor for developing diabetes and therefore, it is possible that metabolic affects of psoriasis may mediate the association of psoriasis and CVD.9,39 Furthermore, a gene related to blood cholesterol levels, APOE4 (apolipoprotein E-4),40 was recently shown to be associated with psoriasis, and this too may be a shared mechanism for increasing coronary risk through lipid pathways. Interestingly, two key inflammatory signalling molecules, TNFAIP3 (tumour necrosis factor inducible protein A20) and its interacting protein TNIP141 were discovered using genome-wide association to be strongly associated with psoriasis. Variation in the TNFAIP3 gene in mice42 and in humans43 has been shown to increase coronary artery disease.

As with all studies, there are important limitations to consider. In database studies, there remains the possibility for misclassification of CV death. If misclassification of CV death is present, such errors would be expected to be non-differential and therefore would bias our results toward the null. Another potential limitation of our study is that we did not examine patients with exclusively incident (new onset) psoriasis. Ideally, an inception cohort study could be performed. However, in diseases such as psoriasis which may not come to medical attention for many years, it is difficult to validly identify truly incident (new onset) cases in a medical records database setting. Finally, although our study suggests that severe psoriasis is an independent risk factor for CV death, it is possible that incomplete measurement of confounders or unknown confounding factors could explain some of the observed association. For example, we did not control for use of specific medications that may alter CV mortality risk, such as angiotensin converting enzyme inhibitors, HMG-CoA reductase inhibitors (statins), and non-steroidal anti-inflammatory drugs. However, our external adjustment analysis reveals that such unmeasured confounding is unlikely to be driving our results.

This study adds to the growing literature suggesting that patients with severe psoriasis are at increased risk of CVD that is not explained by traditional risk factors. This is the first paper to report increased CV mortality in this group of patients while controlling for major cardiovascular risk factors. In this study, severe psoriasis was at least as potent a risk factor for CV death as other major known risk factors such as smoking,44 hyperlipidaemia,45 and hypertension.46 Our results did not show an increase in CV mortality in the presence of hyperlipidaemia, although the results were not statistically significant and therefore should be interpreted cautiously. Although treatment of hyperlipidaemia has been shown to decrease CVD events and subsequent mortality at 1 year,47 no study has shown that hyperlipidaemia is an independent risk factor for CV death after controlling for age, diabetes, tobacco use, and hypertension. In further analyses (data not shown), when we limited the outcome to only MI, consistent with the literature, hyperlipidaemia was an independent risk factor for MI.

This increase in CVD and mortality is important for clinicians to recognize so that counselling and appropriate screening for CVD and its risk factors in patients with severe psoriasis can be implemented.48,49 Future studies are necessary to determine how psoriasis should influence cholesterol treatment targets as outlined by guidelines such as Adult Treatment Panel III, in which clinicians are advised to consider emerging CV risk factors in their treatment decisions. Additionally, future studies are indicated to determine what degree of psoriasis severity translates into clinically significant CV risk, as well as to determine if controlling psoriasis results in reduction of CV risk.

Funding

This work was supported by an unrestricted grant to the Trustees of the University of Pennsylvania from Centocor (J.M.G.), the Psoriasis Research Foundation in Honor of Herman Beerman (J.M.G.) and grant K23AR051125 from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases and grant RO1HL089744 from the National Heart Lung Blood Institute (J.M.G.). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. N.N.M. is a recipient of the American College of Cardiology Young Investigator Award in the Metabolic Syndrome and grant K23HL097151-01.

Conflict of interest. J.M.G. has grants from Amgen, Pfizer, and Abbott, and is a consultant for Amgen, Abbott, Genentech, and Centocor. The other authors confirm that there are no other potential conflicts of interest.

Acknowledgements

We are indebted to Jean Liu and Xingmei Wang for their assistance in creating the analytical dataset.

References

1
Gelfand
JM
Weinstein
R
Porter
SB
Neimann
AL
Berlin
JA
Margolis
DJ
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study
Arch Dermatol
 , 
2005
, vol. 
141
 (pg. 
1537
-
1541
)
2
Kurd
SK
Gelfand
JM
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004
J Am Acad Dermatol
 , 
2009
, vol. 
60
 (pg. 
218
-
224
)
3
Gelfand
JM
Feldman
SR
Stern
RS
Thomas
J
Rolstad
T
Margolis
DJ
Determinants of quality of life in patients with psoriasis: a study from the US population
J Am Acad Dermatol
 , 
2004
, vol. 
51
 (pg. 
704
-
708
)
4
Gelfand
JM
Troxel
AB
Lewis
JD
Kurd
SK
Shin
DB
Wang
X
Margolis
DJ
Strom
BL
The risk of mortality in patients with psoriasis: results from a population-based study
Arch Dermatol
 , 
2007
, vol. 
143
 (pg. 
1493
-
1499
)
5
Azfar
RS
Gelfand
JM
Psoriasis and metabolic disease: epidemiology and pathophysiology
Curr Opin Rheumatol
 , 
2008
, vol. 
20
 (pg. 
416
-
422
)
6
Hansson
GK
Inflammation, atherosclerosis, and coronary artery disease
N Engl J Med
 , 
2005
, vol. 
352
 (pg. 
1685
-
1695
)
7
Hirosumi
J
Tuncman
G
Chang
L
Gorgun
CZ
Uysal
KT
Maeda
K
Karin
M
Hotamisligil
GS
A central role for JNK in obesity and insulin resistance
Nature
 , 
2002
, vol. 
420
 (pg. 
333
-
336
)
8
Cohen
AD
Dreiher
J
Shapiro
Y
Vidavsky
L
Vardy
DA
Davidovici
B
Meyerovitch
J
Psoriasis and diabetes: a population-based cross-sectional study
J Eur Acad Dermatol Venereol
 , 
2008
, vol. 
22
 (pg. 
585
-
589
)
9
Neimann
AL
Shin
DB
Wang
X
Margolis
DJ
Troxel
AB
Gelfand
JM
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
 , 
2006
, vol. 
55
 (pg. 
829
-
835
)
10
Mallbris
L
Granath
F
Hamsten
A
Stahle
M
Psoriasis is associated with lipid abnormalities at the onset of skin disease
J Am Acad Dermatol
 , 
2006
, vol. 
54
 (pg. 
614
-
621
)
11
Mills
CM
Srivastava
ED
Harvey
IM
Swift
GL
Newcombe
RG
Holt
PJ
Rhodes
J
Smoking habits in psoriasis: a case control study
Br J Dermatol
 , 
1992
, vol. 
127
 (pg. 
18
-
21
)
12
Gelfand
JM
Neimann
AL
Shin
DB
Wang
X
Margolis
DJ
Troxel
AB
Risk of myocardial infarction in patients with psoriasis
J Am Med Assoc
 , 
2006
, vol. 
296
 (pg. 
1735
-
1741
)
13
Ludwig
RJ
Herzog
C
Rostock
A
Ochsendorf
FR
Zollner
TM
Thaci
D
Kaufmann
R
Vogl
TJ
Boehncke
WH
Psoriasis: a possible risk factor for development of coronary artery calcification
Br J Dermatol
 , 
2007
, vol. 
156
 (pg. 
271
-
276
)
14
Balci
D
Balci
A
Karazincir
S
Ucar
E
Iyigun
U
Yalcin
F
Seyfeli
E
Inandi
T
Egilmez
E
Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis
J Eur Acad Dermatol Venereol
 , 
2009
, vol. 
23
 (pg. 
1
-
6
)
15
Prodanovich
S
Kirsner
RS
Kravetz
JD
Ma
F
Martinez
L
Federman
DG
Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality
Arch Dermatol
 , 
2009
, vol. 
145
 (pg. 
700
-
703
)
16
von Elm
E
Altman
DG
Egger
M
Pocock
SJ
Gotzsche
PC
Vandenbroucke
JP
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Lancet
 , 
2007
, vol. 
370
 (pg. 
1453
-
1457
)
17
Gelfand
JM
Dattani
H
Margolis
DJ
Strom
BL
The UK General Practice Research Database
Pharmacoepidemiology
 , 
2005
New York
John Wiley and Sons
(pg. 
337
-
346
)
18
Jick
H
Jick
SS
Derby
LE
Validation of information recorded on general practitioner based computerised data resource in the United Kingdom
Br Med J
 , 
1991
, vol. 
302
 (pg. 
766
-
768
)
19
Cox
D
Regression models and life tables
J Roy Statist Soc B
 , 
1972
, vol. 
34
 (pg. 
187
-
220
)
20
Greenland
S
Basic methods for sensitivity analysis of biases
Int J Epidemiol
 , 
1996
, vol. 
25
 (pg. 
1107
-
1116
)
21
Lebwohl
M
Ali
S
Treatment of psoriasis. Part 2. Systemic therapies
J Am Acad Dermatol
 , 
2001
, vol. 
45
 (pg. 
649
-
661
quiz 662–4
22
Prodanowich
S
Ma
F
Taylor
JR
Pezon
C
Fasihi
T
Kirsner
RS
Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis
J Am Acad Dermatol
 , 
2005
, vol. 
52
 (pg. 
262
-
267
)
23
Gelfand
JM
Dommasch
ED
Shin
DB
Azfar
RS
Kurd
SK
Wang
X
Troxel
AB
The risk of stroke in patients with psoriasis
J Invest Dermatol
 , 
2009
, vol. 
129
 (pg. 
2411
-
2418
)
24
Mallbris
L
Akre
O
Granath
F
Yin
L
Lindelof
B
Ekbom
A
Stahle-Backdahl
M
Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients
Eur J Epidemiol
 , 
2004
, vol. 
19
 (pg. 
225
-
230
)
25
O'Malley
T
Ludlam
CA
Riemermsa
RA
Fox
KA
Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes
Eur Heart J
 , 
2001
, vol. 
22
 (pg. 
1226
-
1234
)
26
Libby
P
Inflammation in atherosclerosis
Nature
 , 
2002
, vol. 
420
 (pg. 
868
-
874
)
27
Maradit-Kremers
H
Crowson
CS
Nicola
PJ
Ballman
KV
Roger
VL
Jacobsen
SJ
Gabriel
SE
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study
Arthritis Rheum
 , 
2005
, vol. 
52
 (pg. 
402
-
411
)
28
Warrington
KJ
Kent
PD
Frye
RL
Lymp
JF
Kopecky
SL
Goronzy
JJ
Weyand
CM
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study
Arthritis Res Ther
 , 
2005
, vol. 
7
 (pg. 
R984
-
R991
)
29
Recio-Mayoral
A
Mason
JC
Kaski
JC
Rubens
MB
Harari
OA
Camici
PG
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease
Eur Heart J
 , 
2009
, vol. 
30
 (pg. 
1837
-
1843
)
30
Chodorowska
G
Wojnowska
D
Juszkiewicz-Borowiec
M
C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis
J Eur Acad Dermatol Venereol
 , 
2004
, vol. 
18
 (pg. 
180
-
183
)
31
Ridker
PM
Rifai
N
Rose
L
Buring
JE
Cook
NR
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
N Engl J Med
 , 
2002
, vol. 
347
 (pg. 
1557
-
1565
)
32
Ray
KK
Cannon
CP
Cairns
R
Morrow
DA
Ridker
PM
Braunwald
E
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
Arterioscler Thromb Vasc Biol
 , 
2009
, vol. 
29
 (pg. 
424
-
430
)
33
Huffmeier
U
Lascorz
J
Becker
T
Schurmeier-Horst
F
Magener
A
Ekici
AB
Endele
S
Thiel
CT
Thoma-Uszynski
S
Mossner
R
Reich
K
Kurrat
W
Wienker
TF
Traupe
H
Reis
A
Characterization of Psoriasis Susceptibility Locus 6 (PSORS6) in Patients with Early Onset Psoriasis and Evidence for Interaction with PSORS1
J Med Genet
 , 
2009
, vol. 
46
 (pg. 
736
-
744
)
34
Zeggini
E
Scott
LJ
Saxena
R
Voight
BF
Marchini
JL
Hu
T
de Bakker
PI
Abecasis
GR
Almgren
P
Andersen
G
Ardlie
K
Bostrom
KB
Bergman
RN
Bonnycastle
LL
Borch-Johnsen
K
Burtt
NP
Chen
H
Chines
PS
Daly
MJ
Deodhar
P
Ding
CJ
Doney
AS
Duren
WL
Elliott
KS
Erdos
MR
Frayling
TM
Freathy
RM
Gianniny
L
Grallert
H
Grarup
N
Groves
CJ
Guiducci
C
Hansen
T
Herder
C
Hitman
GA
Hughes
TE
Isomaa
B
Jackson
AU
Jorgensen
T
Kong
A
Kubalanza
K
Kuruvilla
FG
Kuusisto
J
Langenberg
C
Lango
H
Lauritzen
T
Li
Y
Lindgren
CM
Lyssenko
V
Marvelle
AF
Meisinger
C
Midthjell
K
Mohlke
KL
Morken
MA
Morris
AD
Narisu
N
Nilsson
P
Owen
KR
Palmer
CN
Payne
F
Perry
JR
Pettersen
E
Platou
C
Prokopenko
I
Qi
L
Qin
L
Rayner
NW
Rees
M
Roix
JJ
Sandbaek
A
Shields
B
Sjogren
M
Steinthorsdottir
V
Stringham
HM
Swift
AJ
Thorleifsson
G
Thorsteinsdottir
U
Timpson
NJ
Tuomi
T
Tuomilehto
J
Walker
M
Watanabe
RM
Weedon
MN
Willer
CJ
Illig
T
Hveem
K
Hu
FB
Laakso
M
Stefansson
K
Pedersen
O
Wareham
NJ
Barroso
I
Hattersley
AT
Collins
FS
Groop
L
McCarthy
MI
Boehnke
M
Altshuler
D
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes
Nat Genet
 , 
2008
, vol. 
40
 (pg. 
638
-
645
)
35
Kathiresan
S
Willer
CJ
Peloso
GM
Demissie
S
Musunuru
K
Schadt
EE
Kaplan
L
Bennett
D
Li
Y
Tanaka
T
Voight
BF
Bonnycastle
LL
Jackson
AU
Crawford
G
Surti
A
Guiducci
C
Burtt
NP
Parish
S
Clarke
R
Zelenika
D
Kubalanza
KA
Morken
MA
Scott
LJ
Stringham
HM
Galan
P
Swift
AJ
Kuusisto
J
Bergman
RN
Sundvall
J
Laakso
M
Ferrucci
L
Scheet
P
Sanna
S
Uda
M
Yang
Q
Lunetta
KL
Dupuis
J
de Bakker
PI
O'Donnell
CJ
Chambers
JC
Kooner
JS
Hercberg
S
Meneton
P
Lakatta
EG
Scuteri
A
Schlessinger
D
Tuomilehto
J
Collins
FS
Groop
L
Altshuler
D
Collins
R
Lathrop
GM
Melander
O
Salomaa
V
Peltonen
L
Orho-Melander
M
Ordovas
JM
Boehnke
M
Abecasis
GR
Mohlke
KL
Cupples
LA
Common variants at 30 loci contribute to polygenic dyslipidemia
Nat Genet
 , 
2009
, vol. 
41
 (pg. 
56
-
65
)
36
Samani
NJ
Erdmann
J
Hall
AS
Hengstenberg
C
Mangino
M
Mayer
B
Dixon
RJ
Meitinger
T
Braund
P
Wichmann
HE
Barrett
JH
Konig
IR
Stevens
SE
Szymczak
S
Tregouet
DA
Iles
MM
Pahlke
F
Pollard
H
Lieb
W
Cambien
F
Fischer
M
Ouwehand
W
Blankenberg
S
Balmforth
AJ
Baessler
A
Ball
SG
Strom
TM
Braenne
I
Gieger
C
Deloukas
P
Tobin
MD
Ziegler
A
Thompson
JR
Schunkert
H
Genomewide association analysis of coronary artery disease
N Engl J Med
 , 
2007
, vol. 
357
 (pg. 
443
-
453
)
37
Wolf
N
Quaranta
M
Prescott
NJ
Allen
M
Smith
R
Burden
AD
Worthington
J
Griffiths
CE
Mathew
CG
Barker
JN
Capon
F
Trembath
RC
Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease
J Med Genet
 , 
2008
, vol. 
45
 (pg. 
114
-
116
)
38
Kannel
WB
McGee
DL
Diabetes and cardiovascular risk factors: the Framingham study
Circulation
 , 
1979
, vol. 
59
 (pg. 
8
-
13
)
39
Qureshi
AA
Choi
HK
Setty
AR
Curhan
GC
Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses
Arch Dermatol
 , 
2009
, vol. 
145
 (pg. 
379
-
382
)
40
Campalani
E
Allen
MH
Fairhurst
D
Young
HS
Mendonca
CO
Burden
AD
Griffiths
CE
Crook
MA
Barker
JN
Smith
CH
Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin
Br J Dermatol
 , 
2006
, vol. 
154
 (pg. 
345
-
352
)
41
Nair
RP
Duffin
KC
Helms
C
Ding
J
Stuart
PE
Goldgar
D
Gudjonsson
JE
Li
Y
Tejasvi
T
Feng
BJ
Ruether
A
Schreiber
S
Weichenthal
M
Gladman
D
Rahman
P
Schrodi
SJ
Prahalad
S
Guthery
SL
Fischer
J
Liao
W
Kwok
PY
Menter
A
Lathrop
GM
Wise
CA
Begovich
AB
Voorhees
JJ
Elder
JT
Krueger
GG
Bowcock
AM
Abecasis
GR
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways
Nat Genet
 , 
2009
, vol. 
41
 (pg. 
199
-
204
)
42
Idel
S
Dansky
HM
Breslow
JL
A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains
Proc Natl Acad Sci USA
 , 
2003
, vol. 
100
 (pg. 
14235
-
14240
)
43
Boonyasrisawat
W
Eberle
D
Bacci
S
Zhang
YY
Nolan
D
Gervino
EV
Johnstone
MT
Trischitta
V
Shoelson
SE
Doria
A
Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes
Diabetes
 , 
2007
, vol. 
56
 (pg. 
499
-
505
)
44
Doll
R
Peto
R
Wheatley
K
Gray
R
Sutherland
I
Mortality in relation to smoking: 40 years' observations on male British doctors
Br Med J
 , 
1994
, vol. 
309
 (pg. 
901
-
911
)
45
Martin
MJ
Hulley
SB
Browner
WS
Kuller
LH
Wentworth
D
Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men
Lancet
 , 
1986
, vol. 
2
 (pg. 
933
-
936
)
46
MacMahon
S
Peto
R
Cutler
J
Collins
R
Sorlie
P
Neaton
J
Abbott
R
Godwin
J
Dyer
A
Stamler
J
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias
Lancet
 , 
1990
, vol. 
335
 (pg. 
765
-
774
)
47
Cannon
CP
Steinberg
BA
Murphy
SA
Mega
JL
Braunwald
E
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
J Am Coll Cardiol
 , 
2006
, vol. 
48
 (pg. 
438
-
445
)
48
Kimball
AB
Gladman
D
Gelfand
JM
Gordon
K
Horn
EJ
Korman
NJ
Korver
G
Krueger
GG
Strober
BE
Lebwohl
MG
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
J Am Acad Dermatol
 , 
2008
, vol. 
58
 (pg. 
1031
-
1042
)
49
Friedewald
VE
Cather
JC
Gelfand
JM
Gordon
KB
Gibbons
GH
Grundy
SM
Jarratt
MT
Krueger
JG
Ridker
PM
Stone
N
Roberts
WC
AJC editor's consensus: psoriasis and coronary artery disease
Am J Cardiol
 , 
2008
, vol. 
102
 (pg. 
1631
-
1643
)

Comments

0 Comments